Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment
Autore:
Rozenbaum, W; Katlama, C; Massip, P; Bentata, M; Zucman, D; Delfraissy, JF; Trepo, C; David, F; Lanier, ER; Vavro, C; Mamet, JP;
Indirizzi:
Hop Rothschild, F-75571 Paris, France Hop Rothschild Paris France F-75571 op Rothschild, F-75571 Paris, France Grp Hosp Pitie Salpetriere, F-75634 Paris, France Grp Hosp Pitie Salpetriere Paris France F-75634 e, F-75634 Paris, France Hop Purpan, Toulouse, France Hop Purpan Toulouse FranceHop Purpan, Toulouse, France Hop Avicenne, F-93009 Bobigny, France Hop Avicenne Bobigny France F-93009 op Avicenne, F-93009 Bobigny, France Hop Foch, Suresnes, France Hop Foch Suresnes FranceHop Foch, Suresnes, France Hop Kremlin Bicetre, Paris, France Hop Kremlin Bicetre Paris FranceHop Kremlin Bicetre, Paris, France Hotel Dieu, Serv Hepatogastroenterol, Lyon, France Hotel Dieu Lyon France tel Dieu, Serv Hepatogastroenterol, Lyon, France GlaxoWellcome, Marly le Roi, France GlaxoWellcome Marly le Roi FranceGlaxoWellcome, Marly le Roi, France Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA Glaxo Wellcome Inc Res Triangle Pk NC USA 27709 Triangle Pk, NC 27709 USA
Titolo Testata:
ANTIVIRAL THERAPY
fascicolo: 2, volume: 6, anno: 2001,
pagine: 135 - 142
SICI:
1359-6535(200106)6:2<135:TIWAIH>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMMUNODEFICIENCY-VIRUS INFECTION; REVERSE-TRANSCRIPTASE; ANTIRETROVIRAL THERAPY; CUBIC MILLIMETER; CONTROLLED TRIAL; ZIDOVUDINE; LAMIVUDINE; COMBINATION; RESISTANCE; INDINAVIR;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Rozenbaum, W Hop Rothschild, F-75571 Paris, France Hop Rothschild Paris France F-75571 , F-75571 Paris, France
Citazione:
W. Rozenbaum et al., "Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment", ANTIVIR TH, 6(2), 2001, pp. 135-142

Abstract

Objectives: To demonstrate that lamivudine and zidovudine, given separately (lamivudine/zidovudine) or as a single combination tablet (Combivir(TM)),had equivalent efficacy. To evaluate the safety and antiretroviral activity of intensification with abacavir in patients treated with lamivudine/zidovudine for greater than or equal to 12 weeks. Design: A 12-week, equivalence study of lamivudine/ zidovudine versus Combivir. Patients who completed this study could enter a 48-week, intensification study of Combivir plus abacavir. Methods: In the equivalence study, treatment-naive patients were assessed for HIV-1 RNA, CD4 cell count and genotype. The same assessments plus phenotype were made in the intensification study. Serious adverse events were recorded in the equivalence study and all adverse events in the intensification study. Results: Lamivudine/zidovudine (n=40) and Combivir (n=35) gave equivalent reductions in plasma HIV-1 RNA levels at week 12. An identical proportion of patients (74%) in each treatment group harboured virus with the M184V mutation after 12 weeks. Fifty-two patients entered the intensification study and 44 completed 48 weeks of treatment. At the time of intensification withabacavir, all 35 patients with evaluable isolates harboured HIV-1 containing M184V. Addition of abacavir to Combivir led to further decreases in plasma HIV-1 RNA and increases in CD4 cell counts compared with the start of intensification (P<0.001 at week 48). After 48 weeks of triple therapy, multi-nucleoside resistance mutations at codons 69 and 151 were not detected in any patients. All treatment regimens were generally well tolerated. Conclusion: Lamivudine/zidovudine and Combivir have equivalent antiretroviral activity over 12 weeks. Adding abacavir to Combivir can be a safe and effective therapeutic option for patients, including those harbouring virus with the M184V mutation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 04:56:00